-
Spironolactone may save the day with resistant hypertension.
-
Dietary fiber intake appears to lower all-cause mortality, including death from cardiovascular, infectious, and respiratory diseases.
-
Elderly patients with depression respond favorably to bright light treatment.
-
The fda has approved a new topical treatment for head lice infestation.
-
Lower plasma levels of b-amyloid 42/40 in elderly persons followed over 9 years were associated with greater cognitive decline, mainly in those with low measures of past education and literacy.
-
In June 2009, the advisors of the U.S. Food and Drug Administration recommended lowering the maximum dose of over-the counter acetaminophen, which is the key ingredient in such popular products such as Tylenol and Excedrin. The advisors were concerned that severe liver damage and even death can result from excessive ingestion of acetaminophen, which many consumers consider to be easier on the stomach than other medications and safe.
-
Marine n-3 PUFAs act as pleiotropic agents on the cardiovascular system with a diverse range of effects most of which are beneficial for patients with known cardiovascular disease and possibly, they may even have beneficial effects with regard to the primary prevention of cardiovascular disease.
-
An evaluation of medical research by the IOM establishes new RDAs for vitamin D (600-800 IU) and calcium (700-1300 milligrams).
-
Glucosamine sulfate continues to grow in popularity as a treatment for osteoarthritis. Global sales reached almost $2 billion in 2008, an increase of 60 percent over the previous five years.
-
Findings of this ground-breaking randomized controlled trial suggest that patients with irritable bowel syndrome who receive treatment with placebo tablets, and who are fully aware that they are taking a placebo, have significantly greater relief of symptoms compared with patients who receive no treatment at all. Accessing the placebo effect may not require deception at all.